Article
RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer.
British journal of cancer - 1 Jan 2021
Dustin Derek, Gu Guowei, Beyer Amanda R, Herzog Sarah K, Edwards David G, Lin Hangqing, Gonzalez Thomas L, Grimm Sandra L, Coarfa Cristian, Chan Doug W, Kim Beom-Jun, De La O Jean-Paul, Ellis Matthew J, Liu Dan, Li Shunqiang, Welm Alana L, Fuqua Suzanne A W
Abstract excerpt
BACKGROUND: Oestrogen Receptor 1 (ESR1) mutations are frequently acquired in oestrogen receptor (ER)-positive metastatic breast cancer (MBC) patients who were treated with aromatase inhibitors (AI) in the metastatic setting. Acquired ESR1 mutations are associated with poor prognosis and there is a lack of effective therapies that selectively target these cancers. METHODS: We performed a proteomic kinome analysis...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.